Browse Category

NYSE:PFE 18 November 2025 - 5 December 2025

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Pfizer Shares Offer 6.4% Yield, Surpassing Wall Street Optimism After Results
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Inc. remains one of the most closely watched healthcare stocks as of December 3, 2025. The share price is still stuck near post‑COVID lows, but a new $10 billion obesity‑drug acquisition, expanding RSV vaccine markets and a hefty dividend yield around 6.5–7% are reshaping the narrative around the stock. Pfizer+2Pfizer+2
3 December 2025
···
Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Inc. spent Wednesday trading slightly lower despite a stream of fresh headlines that cut both ways for sentiment. The stock hovered around $25.7, giving back a fraction of Tuesday’s nearly 2% gain, as investors weighed upbeat news on obesity drugs, cancer treatment and vaccines against ongoing legal and regulatory risks. MarketScreener+1
26 November 2025
·
Pfizer (PFE) Stock Today: Near‑7% Dividend Yield, Obesity Bet and Pipeline Shift Take Center Stage – November 25, 2025

Pfizer (PFE) Stock Today: Near‑7% Dividend Yield, Obesity Bet and Pipeline Shift Take Center Stage – November 25, 2025

As investors head into the Tuesday, November 25 session, Pfizer Inc. remains one of Wall Street’s most closely watched healthcare names. After a brutal comedown from its pandemic-era highs, the drugmaker is trying to convince the market that a new growth story is taking shape around obesity drugs, oncology and a large – and growing – dividend.
25 November 2025
·
Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer Inc. heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the past few days the pharma giant has closed a multibillion‑dollar obesity acquisition, secured a major new U.S. cancer approval, sold $6 billion in new bonds and agreed to a $41.5 million legal settlement in Texas – while new analysis published today highlights both its long‑term potential and its risks. Reuters+3Pfizer+3Pfizer+3
23 November 2025
··
Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer stock heads into the weekend trading just above $25, with investors digesting a busy week of news: a strong Q3 earnings beat, a fresh FDA cancer-drug approval, completion of a multi‑billion‑dollar obesity deal, a new $6 billion bond issue – and even a headline‑grabbing bird flu case that once again reminds markets of Pfizer’s role in vaccines and antivirals. Benzinga+3Business Wire+3Pfizer+3
23 November 2025
···
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer headlines today include a $41.5 million ADHD drug settlement with Texas, a new antibody discovery deal with Nona Biosciences, and fresh guidance on cost cuts and obesity drugs from the Jefferies Healthcare Conference — here’s what it all means for PFE stock on November 19, 2025.
19 November 2025
····
Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer began marketing a U.S. dollar investment‑grade bond expected to raise at least $5 billion, with the deal structured in as many as seven parts. Early discussions include a 40‑year tranche initially talked around ~125 bps over Treasuries, according to Bloomberg reporting on the transaction. A separate Reuters alert flagged a seven‑part notes offering in a fresh SEC filing, with sizing to be finalized at pricing. Together, the moves point to active balance‑sheet management following the Metsera close. Bloomberg Law+1
18 November 2025
·····
1 … 7 8 9 10 11 12
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Constellation Energy

NASDAQ: CEG 94 / 100
#3 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 92 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

AIG

NYSE: AIG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.